Search hospitals > Illinois > Chicago
University of Illinois at Chicago
Claim this profileChicago, Illinois 60612
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Breast Cancer
Conducts research for Lymphoma
Conducts research for Tumors
906 reported clinical trials
64 medical researchers
Summary
University of Illinois at Chicago is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Leukemia, Breast Cancer, Lymphoma, Tumors and other specialties. University of Illinois at Chicago is involved with conducting 906 clinical trials across 1,118 conditions. There are 64 research doctors associated with this hospital, such as Mary L. Schmidt, Lawrence E. Feldman, Shikha Jain, and Peter Riedell, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Leukemia
Global LeaderStage II
Stage IV
Stage III
Top PIs
Mary L. SchmidtUniversity of Illinois7 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
48 reported clinical trials
99 drugs studied
Lawrence E. FeldmanUniversity of Illinois5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
29 reported clinical trials
42 drugs studied
Shikha JainUniversity of Illinois4 years of reported clinical research
Studies Adenocarcinoma
Studies Colorectal Cancer
16 reported clinical trials
35 drugs studied
Peter Riedell, MDUniversity of Chicago3 years of reported clinical research
Expert in Lymphoma
Studies B-Cell Lymphoma
15 reported clinical trials
26 drugs studied
Clinical Trials running at University of Illinois at Chicago
Prostate Cancer
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Multiple Myeloma
Squamous Cell Carcinoma
Anal Cancer
Astrocytoma
Plasma Cell Neoplasms
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting2 awards Phase 3
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Illinois at Chicago?
University of Illinois at Chicago is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Leukemia, Breast Cancer, Lymphoma, Tumors and other specialties. University of Illinois at Chicago is involved with conducting 906 clinical trials across 1,118 conditions. There are 64 research doctors associated with this hospital, such as Mary L. Schmidt, Lawrence E. Feldman, Shikha Jain, and Peter Riedell, MD.
Where is University of Illinois at Chicago located?
The University of Illinois Hospital is situated at 1740 W Taylor St, Chicago, IL 60612, within the Illinois Medical District. For those driving, access is via the I-90/I-94 W, exit 50A for Damen Ave, then a right onto Taylor St. Public transportation is available through the CTA Pink Line Polk Station, conveniently located within walking distance.
Who should I call to ask about financial aid or insurance network?
**University of Illinois at Chicago (UIC) Hospital Financial Assistance and Insurance Contacts**
**Financial Assistance:**
- **Phone:** 312.413.7621
- **Email:** getinsured@uic.edu
- **Address:** Financial Counselor, University of Illinois Hospital & Health Sciences System, 1740 W. Taylor St., Chicago, IL 60612
- **Website:** [Financial Assistance Information](https://hospital.uillinois.edu/patients-and-visitors/patient-information/financial-assistance)
**Insurance Inquiries:**
- **Phone:** 312.413.7621
- **Website:** [Insurance Information](https://www.uic.edu/apps/departments-az/search?dispatch=find&orgid=99946)
For details on financial assistance programs, insurance options, and the application process for financial aid, please contact the respective departments.
What insurance does University of Illinois at Chicago accept?
The University of Illinois at Chicago (UIC) accepts a wide range of insurance plans, including but not limited to Blue Cross Community MMAI, Campus Care, County Care, Harmony, Illinicare, Meridian, Molina, Next Level, and Blue Cross Community Family Health Plan (FHP). UI Health also participates in Medicare and various health plans such as Aetna, BCBSIL, Blue Advantage HMO, Blue Choice Opt PPO, Blue Choice PPO, Blue Choice Preferred PPO, Blue Cross Community Medicaid, and more. For international students, it's crucial to ensure that their health insurance coverage meets all J-1 Exchange Visitor requirements.
What awards or recognition has University of Illinois at Chicago received?
The University of Illinois Hospital & Health Sciences System, located in Chicago, Illinois, is renowned for its extensive research across multiple disciplines including alternative, complementary, and traditional medicine, biotechnology and biodefense, cancer biology, drug discovery, infectious diseases, neuroscience, and patient safety. It has garnered numerous research grants, with its researchers acclaimed globally. Furthermore, the University of Illinois at Chicago (UIC) annually hosts the Research and Scholarship Award competition, honoring significant contributions to research and scholarship at UIC.